 Jounce Therapeutics NASDAQ: JNCE stock jumped after it sold rights to a cancer drug to Gilead Sciences NASDAQ: GILD . Shares were trading as high as 1.30 in the pre-market, after closing under 75 cents on Dec. 27. 